Aotecar Biology: Plans to repurchase shares worth 1-2 billion yuan to reduce registered capital.

AITAI Biology announced that the Company's controlling shareholder, actual controller, and chairman Gao Fei proposed to repurchase shares through the centralized competitive trading method, which has been approved by the shareholders' meeting. The amount of this repurchase is not less than 100 million yuan, not more than 200 million yuan, at a price not exceeding 85 yuan per share. It is expected to repurchase 1.1765-2.3529 million shares, accounting for 1.48%-2.97% of the total share capital. The funds come from the proceeds of the initial public offering of shares, and will be used to reduce the registered capital. The repurchase period is 12 months from the approval of the shareholders' meeting, and relevant personnel have no plans to reduce their holdings in the next 3-6 months. In addition, this repurchase carries risks such as price changes and changes in the plan.